On Nov 2, 2021 Biolinq closed a Series B round and raised $100,000,000 from Able Partners, Aphelion Capital, Ascensia Diabetes Care, AXA Investment Managers, Cirrus Logic, EOFlow, Falcon Edge Capital, Global Health Funds, Hikma Ventures, JDRF T1D Fund, Longevity Vision Fund, M Ventures, RiverVest, Senvest Management, T&W Medical, Taisho Pharmaceutical Holdings, The Broe Group, featuring lead investors RiverVest.

About the company: Biolinq is located at United States, North America.
“”

Company website: http://www.biolinq.me